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Outcomes Study of hepatic
encephalopathy Patients’ Experience on
Rifaximin-α (PROSPER): an observational
study among 550 patients
Aleksander Krag1*, Marcus Schuchmann2, Hanna Sodatonou3, Jeff Pilot3, James Whitehouse4,
Simone I. Strasser5 and Mark Hudson6Abstract
Background: Hepatic encephalopathy (HE) is one of the most important severe complications of liver cirrhosis.
Thought to be caused by elevated blood levels of gut-derived neurotoxins (particularly ammonia) entering the
brain, HE manifests as a wide range of neurological or psychiatric abnormalities, which increase the risk of mortality,
result in substantial morbidity and negatively affect the quality of life (QoL) of both patients and their caregivers. HE
is also associated with a substantial economic burden. Rifaximin-α 550 mg is a locally acting oral antibiotic that
reduces the effects of ammonia-producing intestinal flora, and which is used to help reduce the recurrence of overt
HE. The efficacy of rifaximin-α 550 mg was established in a randomised controlled trial and long-term extension
study. However, ‘real-world’ evidence is also required to assess how this efficacy may translate into effectiveness in
clinical practice, including the potential impact of treatment on healthcare resource utilisation.
Methods: The Prospective Real-world Outcomes Study of HE Patients’ Experience on Rifaximin-α 550 mg (PROSPER) is
a multinational, multicentre, observational study that will be conducted under real-world clinical practice conditions.
Comprising a retrospective phase (up to 12 months) and a prospective phase (up to 24 months), and employing a
robust statistical methodology, PROSPER has been specifically designed to minimise the bias associated with
observational studies. The primary endpoint will be the effect of rifaximin-α 550 mg treatment on HE- and liver-related
hospitalisation rate and duration of hospitalisation. Secondary endpoints will include comprehensive assessments of
the impact of treatment on the QoL and workplace productivity of patients and caregivers, a global assessment of
treatment effectiveness and safety/tolerability. Approximately 550 patients will be enrolled.
Conclusions: PROSPER will provide valuable real-world information on the effectiveness of rifaximin-α 550 mg in
reducing the recurrence of HE, and its impact on the QoL and work productivity of patients and their caregivers. By
providing data on both the direct costs (e.g., hospitalisation rate, duration of hospitalisation) and indirect costs (such as
work productivity) of HE, PROSPER should help confirm whether rifaximin-α 550 mg treatment represents a good use
of economic resources.
Trial registration: ClinicalTrials.gov identifier NCT02488993.
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Hepatic encephalopathy (HE) is a brain dysfunction
caused by liver insufficiency and/or portosystemic shunt-
ing, which manifests as a wide spectrum of neurological
or psychiatric abnormalities [1]. It is now widely recog-
nised as one of the most important severe complications
of liver cirrhosis, along with conditions such as ascites
and variceal bleeding [1]. HE severity is categorised
using West Haven criteria from ‘minimal’ through grade
1 to 4 [1]. ‘Covert HE’ is defined as West Haven minimal
and grade 1, and ‘overt HE’ is defined as West Haven
grades 2 to 4 [1]. Overt HE occurs in 30–40% of patients
with cirrhosis at some time during their clinical course
[1]. HE increases the risk of mortality [2] and is one of
the most debilitating complications of liver disease [1],
negatively affecting the lives of both patients and care-
givers [1, 3].
HE is also associated with a substantial economic bur-
den, in terms of direct healthcare costs resulting from,
for example, emergency room visits and hospitalisation
[1, 4–11]. Although difficult to accurately determine, the
indirect costs of HE (e.g., loss of work productivity, car
accidents) also represent a substantial economic burden,
which is likely to be further increased when the impact
on caregivers is taken into account [3, 7, 12].
The neuropsychiatric symptoms of HE are thought
to result from elevated blood levels of gut-derived
neurotoxins (particularly ammonia), which enter the
brain due to the inability of the cirrhotic liver to re-
move them from the blood [13]. Rifaximin-α 550 mg
is a locally acting oral antibiotic that is minimally
absorbed in the gut to reduce the effects of intestinal
flora, including ammonia-producing species [14]. Its
clinical activity may be due to its effects on the meta-
bolic function of gut microbiota, rather than a change
in relative bacterial abundance [15]. Rifaximin-α
550 mg is indicated in Europe for the reduction in re-
currence of episodes of overt HE in patients aged
≥18 years [16]. In Australia, it has the same indica-
tion, but is restricted to where other treatments have
failed or are contraindicated [17]. The efficacy of
rifaximin-α 550 mg has been confirmed in a rando-
mised controlled trial (RCT), in which rifaximin-α
550 mg twice daily (administered concomitantly with
lactulose therapy in approximately 91% of patients) re-
duced the relative risks of recurrence of overt HE and
HE-related hospitalisation by 58% and 50%, respect-
ively, compared with placebo (absolute risk reductions:
24% and 9%, respectively) [18]. In a subsequent 2-year
extension study, long-term treatment with rifaximin-α
550 mg (with concomitant lactulose in approximately
90% of patients) provided a continued reduction in
the rate of HE-related and all-cause hospitalisation,
without an increased rate of adverse events [19].Although RCTs are essential in the clinical develop-
ment of new treatments, they do not necessarily reflect
clinical practice conditions. Typically, they are con-
ducted in carefully defined patient populations using
specific inclusion and exclusion criteria. By contrast, in
clinical practice, patients are more diverse in terms of
clinical characteristics than those recruited for RCTs. In
addition, whereas RCTs employ rigid treatment proto-
cols, in clinical practice treatment is tailored on a
patient-by-patient basis. Consequently, ‘real-world’
studies are required to complement evidence from RCTs
by determining how the efficacy of an agent translates
into effectiveness in clinical practice. Since real-world
studies have a higher likelihood of inherent bias than
RCTs, it is important when designing a real-world study
to eliminate as much bias as possible and minimise the
impact of any remaining bias in the statistical analysis
methodology employed. Real-world data are particularly
useful for hard-to-reach patient populations (such as HE
patients), for which clinical trial recruitment is challen-
ging. Moreover, national reimbursement authorities are
increasingly requesting real-world data to support evi-
dence from clinical trials when examining the economic
rationale for supporting new treatments [20, 21]. Real-
world studies are therefore important both clinically and
from a patient access perspective.
An important aspect of real-world studies is to assess
patient- and caregiver-reported outcomes, since the
effectiveness of a treatment is not only dependent on its
efficacy and safety/tolerability, but also on its effects on
the patient’s quality of life (QoL) and ability to function,
and the associated impact on those who care for them.
This is particularly true for chronic conditions, such as
HE, where an agent’s effectiveness relies primarily on the
patient being willing and able to be compliant with the
treatment over the long term.
We here describe the design of the Prospective Real-
world Outcomes Study of HE Patients’ Experience on
Rifaximin-α 550 mg (PROSPER), which will evaluate the
clinical effectiveness of rifaximin-α 550 mg and its im-
pact on healthcare resources when used for the manage-
ment of HE in routine clinical practice.Methods/design
PROSPER is a multinational, multicentre, observational
study that will be conducted in secondary/tertiary care
centres across Europe and Australia (ClinicalTrials.gov
identifier: NCT02488993). Study site selection will be
based on an initial feasibility assessment to evaluate
the volume of patients seen and local expertise in
HE at potential centres. The principal country for
patient recruitment will be Denmark, where no eth-
ical approval is required for observational studies.
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sought, where appropriate.Study design
PROSPER will be conducted under ‘real-world’ clinical
practice conditions. Consequently, no changes to the
management of HE patients will be made for the
purposes of the study.
Once eligible patients have been recruited and con-
sented to participate in the study, two data collection
phases will be undertaken (Fig. 1). The first will be a
retrospective phase, involving the review of the patients’
medical records and electronic hospital admissions data.
Up to 12 months of data prior to study entry will be
reviewed and collected. The level and nature of missing
data will be assessed and accounted for in the statistical
analysis plan, if necessary. The retrospective phase will
be followed by a prospective phase, during which data
will be collected from all patients either receiving
rifaximin-α 550 mg (rifaximin-α 550 mg cohort) or not
receiving rifaximin-α 550 mg (control cohort) from the
point of study entry. Up to 24 months of data following
study entry will be collected and analysed.
In order to minimise bias and the influence of con-
founding factors, the study outcomes will be compared
between the treatment cohorts in three ways (Fig. 1). The
first approach will initially involve the clinical character-
isation of the study population, based on retrospective
chart review (Fig. 1, comparison 1a), following which out-
comes between the cohorts will be compared after adjust-
ment of statistical methods on the basis of the findings
from comparison 1a (Fig. 1, comparison 1b). Secondly, for
each cohort individually, outcomes pre and post baseline
will be compared (Fig. 1, comparisons 2a and 2b). Thirdly,
the difference between the two cohorts in pre/post
changes will be compared (Fig. 1, comparison 3).Fig. 1 Study designPatients will be eligible to enrol during or following hos-
pitalisation for the qualifying episode of overt HE (Fig. 2;
timepoint 1). Patients will also be eligible to enter the
study at the time of resolution of the qualifying episode of
overt HE (Fig. 2; timepoint 2) or at a follow-up appoint-
ment, providing this is within 12 weeks of resolution of
the qualifying episode of overt HE (Fig. 2; timepoint 3).Study population
Patients with cirrhosis and HE will be enrolled into
PROSPER. The study will employ a limited number of
inclusion and exclusion criteria in order to reflect the
diversity of patients encountered in clinical practice
(Table 1).Study assessments
The study’s primary endpoint will be the HE- and liver-
related hospitalisation rate and the resulting duration of
hospitalisation (number of bed-days). Secondary end-
points will include the rate of all-cause hospitalisation and
the resulting duration of hospitalisation (number of bed-
days), mortality rate, and the number, duration and sever-
ity of HE episodes. Effects of treatment on the underlying
liver disease will also be assessed as secondary endpoints
using the Child-Turcotte-Pugh score, Model for End-stage
Liver Disease (MELD) score or MELD-Na score (a modi-
fied MELD score including serum sodium [22]). In
addition, the effectiveness of treatment will be assessed by
the patient, caregiver and physician, using the Global
Evaluation of Treatment Effectiveness (GETE) question-
naire. This consists of the single question ‘How effective
has [your treatment/the treatment] been in controlling
[your/the patient’s] HE?’, which is answered by choosing
one of five responses: ‘Complete control of HE’, ‘Marked
improvement in HE’, ‘Limited improvement in HE’, ‘No ap-
preciable change in HE’ or ‘Worsening of HE’.
Fig. 2 Timing of entry into study, relative to overt HE episode. HE, hepatic encephalopathy
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be evaluated by assessing the frequency and nature of
adverse events (AEs) and serious AEs. This will include
classification of the severity of AEs and their relation-
ship/causality in relation to medical treatment of HE.
The effects of treatment on health-related QoL will be
assessed using the patient-reported Chronic Liver Disease
Questionnaire (CLDQ) [23], the patient-reported Euroqol-5
Dimension-5 level (EQ-5D-5L) measure and the caregiver-
reported proxy EQ-5D-5L:1 measure [24]. The CLDQ is a
29-item questionnaire assessing a wide range of physical,
emotional and psychosocial QoL-related factors during the
previous 2 weeks [23]. The EQ-5D-5L and proxy EQ-5D-
5L are six-item questionnaires assessing the patient’s mobil-
ity, ability to self-care, ability to undertake usual activities,
pain/discomfort, anxiety/depression and overall health
status on the particular day in question [24].
Workplace productivity impairment will be assessed in
patients using the Work Productivity and Activity Impair-
ment Questionnaire: General Health V2.0 (WPAI:GH)
and in caregivers using the Work Productivity and
Activity Impairment Questionnaire: General Health Care
Giving V2.0 (WPAI:GH-CG) [25]. These are six-itemTable 1 Inclusion and exclusion criteria
Inclusion criteria
• Diagnosis of cirrhosis
• Age ≥ 18 years
• Enrolment within 12 weeks of resolution
of an episode of overt HE associated with a
hospital visit
• Ability to provide informed consent
• Clinical eligibility to receive rifaximin-α 550 mg,
in the opinion of the participating physician, regardless
of HE treatment actually received
HE hepatic encephalopathy
aAll types and dose strengths of rifaximinquestionnaires assessing the effects of the patient’s health
problems (WPAI:GH), or the effects of caregiving for
the patient’s health problems (WPAI:GH-CG), on the
individual’s ability to work and perform daily activities. A
schedule for these assessments is shown in Table 2.Sample size calculation
In observational studies where multivariable modelling
is expected to be performed, the study should have at
least 10 events for every variable included in the model.
Therefore, in order to consider approximately 10
variables, 100 events would need to be observed in each
of the study cohorts (patients receiving and not receiving
rifaximin-α 550 mg). On the basis of an open-label
maintenance study of rifaximin-α 550 mg in patients
with HE [19], approximately 45% of patients would be
expected to have experienced a hospitalisation within
the first 12 months of follow-up. Assuming a dropout
rate of 10%, approximately 247 patients would be
required for each of the two cohorts, or 494 patients
overall. Thus, a total study population of 550 would be
sufficient to assess the primary endpoint of the study atExclusion criteria
• West Haven score of ≥2 at study entry
• A mental health disorder that makes HE diagnosis
questionable (e.g., dementia, psychosis)
• Prior treatment with rifaximina within 12 months
prior to the qualifying overt HE episode
• Contraindications to the use of rifaximin-α 550 mg,
as per the local Summary of Product Characteristics [16, 17]
Table 2 Schedule of assessments
Enrolment 1 montha 3 monthsa 6 monthsa 12 monthsa 18 monthsa 24 monthsa
Informed consent provided by patient and
caregiver (note that caregiver consent is
optional for patient study inclusion)
X
Retrospective chart review (collection of
demographic and medical history data)
X
Ongoing clinical data, including clinical
outcomes, laboratory measures, medication
dose/schedule, resource utilisation,
medication adherenceb
X X X X X X
GETEc X X
CLDQb X X X
EQ-5D-5L (patient)d X X X X X X
EQ-5D-5L Proxy (caregiver)d,e X X X X X X
WPAI (patient)c X X X X X X
WPAI (caregiver)c X X X X X X
CLDQ Chronic Liver Disease Questionnaire, EQ-5D-5 L Euroqol-5 Dimension-5 level measure, GETE Global Evaluation of Treatment Effectiveness questionnaire, WPAI
Work Productivity and Activity Impairment questionnaire
aTarget dates only; flexible depending on patient response
bTo be collected at all clinic visits but not at fixed time intervals; clinic visits will be scheduled by investigator and patient according to normal management and
not defined by study protocol
cTo be collected at the clinic visit closest to the indicated study date; no additional clinic visits to be scheduled for study participation
dTo be requested for patient completion via paper submission or online portal or at clinic visit closest to the indicated date; clinic visit may not be required
eAustralia, UK, Ireland, France and Germany, where the proxy response has been validated
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cision following the full 24-month follow-up period.
Statistical analysis
A primary aim of PROSPER will be to minimise any
bias typically associated with observational studies.
This will be achieved by the three-step comparative
structure incorporated into the study’s design (as
described above) and the associated statistical methodology.
An overview of the statistical considerations is presented
here.
The primary outcome of HE- and liver-associated hospi-
talisation rate will be analysed as a count, using either
Poisson or negative binomial regression, depending on the
level of observed dispersion. An offset term will be
included to account for length of time eligible to experi-
ence a hospitalisation, accounting for mortality or other
competing risk events. The primary outcome of duration
of HE- and liver-associated hospitalisation (number of
bed-days) will be analysed either as a continuous variable
or a count, depending on the observed distribution. Meth-
odologies such as median regression may be employed to
account for the likelihood of right skew resulting from a
small proportion of extended hospital stays. Comparison
of the primary outcomes between treatment cohorts will
adjust for key covariates using either multivariable regres-
sion analysis or a propensity score analysis (to be con-
firmed based on an exploratory review of the data). Due
to the observational nature of the study, it is expected that
some patients could change, discontinue or be non-compliant with therapy during the course of follow-up.
These scenarios will be considered during statistical
analysis and techniques that account for exposure to
therapy will be applied, if applicable.
The rate of all-cause hospitalisation and the resulting
duration of hospitalisation will be analysed in the same
way as the primary endpoints. Numeric measures (e.g.,
CLDQ, EQ-5D-5L and GETE scores) will be analysed
using a linear regression model, with longitudinal
methodology to account for repeated measures, if
applicable. Event-based variables and count data (e.g.,
AEs, HE episodes, mortality) will be analysed using
Poisson or negative binomial regression, with offset
terms to account for exposure time, length of time
eligible to receive hospitalisation and competing risks
(e.g., death); analyses will also adjust for underlying dif-
ferences between cohorts (i.e., confounding factors).
Time-to-event methods (e.g., Kaplan Meier analysis)
will be used for variables such as time until death. Cat-
egorical demographic and clinical characteristics will be
presented descriptively as frequency/percentage distri-
bution and compared using a chi-squared test. Con-
tinuous demographic and clinical characteristics will be
presented descriptively as means with 95% confidence
intervals and compared using a Student’s t-test.
It is anticipated that additional analyses will include
treatment adherence and switching, and the integration
of survival data with QoL data, to assess quality-adjusted
life-years (QALYs). Other exploratory analyses may also
be conducted.
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PROSPER aims to enrol approximately 550 patients. Patient
recruitment commenced in June 2015. An interim analysis
will be performed after 12 months of data collection.
Additional ad hoc and exploratory analyses may also occur
during the course of data collection. The full dataset should
be available for analysis by January 2020.
Discussion
Data on the real-world effectiveness of secondary prophy-
laxis with rifaximin-α 550 mg and its impact on healthcare
resource utilisation are currently limited. Although several
studies have been conducted in the USA [7, 26–29],
studies in Europe are scarce and none have yet been
published in Australia. In the UK retrospective observa-
tional IMPRESS study, details of inpatient hospitalisations
and hospital visits in the 12 months prior to and following
initiation of rifaximin-α 550 mg treatment for HE were
extracted from 11 NHS Trust electronic databases [4]. A
total of 145 patients were evaluated (mean age 61 years;
61% male), 82% of whom were being treated with lactu-
lose. A comparison of resource use in the 12 months pre-
and post-initiation of rifaximin-α 550 mg revealed that
there were significant reductions in the number of
hospitalisations with overnight stay per patient (mean 2.7
vs. 1.7; p = 0.002), total number of bed days per inpatient
(mean 31.7 vs. 16.4; p < 0.001) and number of critical care
bed days per inpatient (mean 11.3 vs. 2.4; p = 0.017). The
number of emergency room visits per patient also
decreased but the difference was not statistically signifi-
cant (mean 2.4 vs. 1.8; p = 0.099). Treatment with
rifaximin-α 550 mg was generally well tolerated: three
patients (2%) had adverse drug reactions and four (3%)
developed C. difficile infection, but none of these patients
discontinued treatment [4].
Another UK study specifically assessed the impact of
rifaximin-α 550 mg treatment on healthcare resource
utilisation using data from seven liver treatment centres
[30]. Clinical, demographic and hospital admissions data
from 326 patients were collected retrospectively for the
time-periods 3, 6 and 12 months before and following
initiation of rifaximin-α 550 mg treatment, and admis-
sion rates and hospital length of stay before and during
therapy were compared. Rifaximin-α 550 mg treatment
reduced the total length of stay in hospital by an
estimated 31–53%, decreasing inpatient costs by £4858–
6607 per patient per year. When the cost of treatment
was taken into account (£3379 per patient per year), the
estimated annual mean saving was £1480–3228 per
patient [30].
Other data from Europe on the impact on healthcare
resource utilisation are the results of cost-effectiveness
modelling analyses conducted for the UK, Belgium,
Sweden and the Netherlands [8–11], which appliedcountry-specific costings to data derived from the
original rifaximin-α 550 mg RCT [18] and open-label
extension study [19]. The UK analysis found that the
5-year average cost of care for HE with rifaximin-α
550 mg plus lactulose was £22,971, a saving of £573
compared with the 5-year average cost of standard care
(placebo plus lactulose) [8]. The corresponding values for
benefit were 2.4 and 1.8 QALYs, respectively, representing a
dominant base-case incremental cost-effectiveness ratio
(ICER) over a 5-year horizon for rifaximin-α 550 mg. The
positive impact of rifaximin-α 550 mg on healthcare costs
was due to its reducing the rate of overt HE episodes, the
likelihood of hospitalisation and hospital length of stay [8].
Similarly, beneficial cost-effectiveness results for rifaximin-
α 550 mg treatment were demonstrated in modelling
analyses conducted for Belgium and Sweden [9, 10]. The
analysis conducted for the Netherlands incorporated indir-
ect costs into the model, in terms of loss of work productiv-
ity and the costs of travelling to attend outpatient visits
[11]. The time horizon was again 5 years, and costs and
benefits were discounted at 4.0% and 1.5%, respectively.
The total discounted and undiscounted 5-year costs for
a patient treated with rifaximin-α 550 mg plus lactulose
were €67,018 and €87,154, respectively, compared with
€37,365 and €45,755, respectively, for a patient treated
with placebo plus lactulose. Although the cost of lost
productivity was higher for placebo plus lactulose than
for rifaximin-α 550 mg plus lactulose (because of more
frequent overt HE events), travel and informal costs
were higher for rifaximin-α 550 mg plus lactulose than
for placebo plus lactulose due to increased survival.
The incremental health benefits for rifaximin-α 550 mg
over a lifetime scenario were 0.93 QALYs (discounted)
and 1.09 (undiscounted). Although the ICER amounted
to €31,897 per QALY (discounted) and €38,027 per QALY
(undiscounted), these values were well below the thresh-
old recommended by the country’s Scientific Council for
Government Policy (€80,000 per QALY) [11].
Although encouraging, these cost-effectiveness
analyses were modelled using RCT data and their
results therefore need to be confirmed with real-world
evidence. PROSPER will address this need by providing
valuable real-world information on the impact of
rifaximin-α 550 mg treatment in Europe and Australia
on both the direct costs (e.g., hospitalisation rate, dur-
ation of hospitalisation) and indirect costs (e.g., work
productivity) of HE. PROSPER could also afford a better
understanding of the burden and natural history of HE,
and of variability in disease management between differ-
ent countries and regions. Additionally, PROSPER is likely
to provide the type of evidence required by payors and
decision bodies to confirm whether rifaximin-α 550 mg
treatment represents a good use of economic resources
(as indicated by cost-effectiveness models), thereby
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right patients.
Since the findings and implications of real-world studies
are often limited by bias, PROSPER has been specifically
developed to minimise bias, in terms of both its design
and the robust statistical methodology it employs. As
such, it is broadly in line with the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
Good Research Practices Taskforce guidelines, which state
that the choice of study design may strengthen the ability
to address potential biases and confounding in prospective
observational studies, separately from the analytic and
statistical approaches employed [20]. The details provided
in the present article also address the guidelines’ recom-
mendation that the reasoning behind all study design and
analytic choices should be transparent and explained in
the study protocol [20].
The ISPOR guidelines acknowledge the increasing
importance of real-world studies in informing health
policy decisions and highlight the consequent necessity
for rigour and transparency when conducting such studies
[20]. In addressing these concerns, it is anticipated that
the findings of PROSPER will be widely applicable to
clinical practice and may help inform future approaches
to HE management.
Conclusions
PROSPER will provide valuable real-world information
on the effectiveness of rifaximin-α 550 mg in reducing
the recurrence of HE, and its impact on the QoL and
work productivity of patients and their caregivers.
PROSPER will also help to confirm whether rifaximin-α
550 mg treatment is cost effective, by providing real-
world information on its impact on both the direct and
indirect costs of HE.
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